<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02846103</url>
  </required_header>
  <id_info>
    <org_study_id>P/2013/207</org_study_id>
    <nct_id>NCT02846103</nct_id>
  </id_info>
  <brief_title>Study of Anti-telomerase T CD4 Immunity in Metastatic Lung Cancer</brief_title>
  <acronym>Telocap02</acronym>
  <official_title>Study of Anti-telomerase T CD4 Immunity in Metastatic Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing evidence suggests that immune responses might be a determining factor in lung&#xD;
      cancer tumor progression.&#xD;
&#xD;
      The impressive clinical responses obtained with immune checkpoint inhibitors&#xD;
      (anti-PD-1/PDL-1, anti-CTLA-4) indicate that the presence of preexisting antitumor immune&#xD;
      response is required for their efficacy and highlight the critical role of antitumor T cell&#xD;
      immunity. Recent progress on the fields of tumor immunology underlines the critical role of&#xD;
      CD4 helper 1 T lymphocyte (TH1) in the control of innate and adaptive anticancer immunity.&#xD;
      Therefore, monitoring tumor specific TH1 response could be relevant in cancer patients.&#xD;
&#xD;
      In order to monitor tumor-specific CD4 Th1 responses in most cancer patients, the&#xD;
      investigators group have previously described novel promiscuous peptides (referred as&#xD;
      UCP:Universal Cancer Peptides) derived from human telomerase (TERT), a prototype of shared&#xD;
      tumor antigen.&#xD;
&#xD;
      By using UCP-based immuno-assay, pre-existing UCP-specific Th1 responses have been detected&#xD;
      in the blood of lung cancer patients (Telocap01). The frequency and magnitude of this&#xD;
      response were inversely correlate to the disease stage. Furthermore, UCP-specific responses&#xD;
      were significantly found in patients with low PD1+ and TIM3+ T cells.&#xD;
&#xD;
      Then in TeloCap02 study, UCP specific Th1 immune responses will be evaluated in lung cancer&#xD;
      before and after treatment (chemotherapy, immunotherapy).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>date of death from any cause (within 2 years after the initiation of the treatment)</time_frame>
    <description>time between the date of initiation of treatment and the date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UCP-specific Th1 responses measured by ELISPOT assay</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>date of first progression of the disease (within 2 years after the initiation of the treatment)</time_frame>
    <description>time interval between the date of initiation of treatment and the date of first progression (local, remote [extent of the disease by RECIST v1.1] second cancer) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life related to health measured by EORTC-QLQC30 and LC13 questionaries.</measure>
    <time_frame>from the inclusion to patient death, up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Biological samples</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood samples will be collected at baseline, after the first-line therapy and at 12 months.&#xD;
Tumor tissues will be collected if available.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological samples</intervention_name>
    <description>blood and tumor tissue samples</description>
    <arm_group_label>Biological samples</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed NSCLC (Non Small Cell Lung Cancer) or SCLC&#xD;
             (small cell lung cancer)&#xD;
&#xD;
          -  stade IIIb or metastatic&#xD;
&#xD;
          -  Patient candidate to a first-line therapy&#xD;
&#xD;
          -  Performance status 0, 1 or 2 on the ECOG scale&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of adjuvant chemotherapy for lung cancer treatment&#xD;
&#xD;
          -  Patients under chronic treatment with systemic corticoids or other immunosuppressive&#xD;
             drugs (prednisone or prednisolone ≤ 10 mg/day is allowed)&#xD;
&#xD;
          -  Prior history of other malignancy except for: basal cell carcinoma of the skin,&#xD;
             cervical intra-epithelial neoplasia and other cancer curatively treated with no&#xD;
             evidence of disease for at least 5 years&#xD;
&#xD;
          -  Active autoimmune diseases, HIV, hepatitis C or B virus&#xD;
&#xD;
          -  Patients with any medical or psychiatric condition or disease,&#xD;
&#xD;
          -  Patients under guardianship, curatorship or under the protection of justice.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier ADOTEVI, Pr</last_name>
    <email>olivier.adotevi@univ-fcomte.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Virginie WESTEEL, Pr</last_name>
    <email>virginie.westeel@univ-fcomte.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Virginie WESTEEL, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Foucher, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruno COUDERT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alain PREVOST, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabeth QUOIX, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, Benhamouda N, Cazes A, Le Pimpec-Barthes F, Gaugler B, Langlade-Demoyen P, Pivot X, Saas P, Maillère B, Tartour E, Borg C, Adotévi O. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res. 2012 May 15;18(10):2943-53. doi: 10.1158/1078-0432.CCR-11-3185. Epub 2012 Mar 8.</citation>
    <PMID>22407833</PMID>
  </reference>
  <reference>
    <citation>Godet Y, Dosset M, Borg C, Adotevi O. Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer? Oncoimmunology. 2012 Dec 1;1(9):1617-1619.</citation>
    <PMID>23264913</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

